Lectrona logo Boehringer Ingelheim

Funding Opportunities
for External Collaborative
Research (ECR)

External Collaborative Research
(ECR)

The Boehringer lngelheim ECR Program is offered to all qualified academic and community-based scientists or consortiums that are interested in proposing a research study and wish to collaborate with Boehringer lngelheim to further develop a protocol and analyze and publish the results. In addition to providing intellectual contributions, Boehringer lngelheim may provide drug product and/or financial support for an approved ECR. Boehringer lngelheim does not serve as the Regulatory Sponsor for ECR.

The preliminary budget for ECR studies should reflect fair market value for all costs and cannot include direct salary support for the Principal Investigator. Budgets for ECR will be further negotiated pending finalization of the collaborative protocol.

While the research interests listed within the therapeutic areas are of focus to Boehringer Ingelheim, other novel research interests may be considered.

Cardiometabolism

Key areas of interest for External Collaborative Research:

  • Understand the role of empagliflozin in the treatment of T2DM with one or more of the following: ASCVD, HF (acute, worsening of, and chronic) and/or CKD.
  • Understanding trends of utilization of empagliflozin in subgroup populations (e.g., Women, African Americans, Hispanics, etc.) with type 2 diabetes (T2D) and one of the following: cardiovascular disease (CVD), heart failure (HF) or chronic kidney disease (CKD)
  • Understanding the extent of real-world implementation of guideline-based management of patients with type 2 diabetes (T2D) and one of the following: CVD, HF or CKD
  • Research focused on symptom burden in heart failure: Quality Of Life (QOL), symptom management, Patient Reported Outcomes (PRO) and other patient-centric aspects of heart failure
  • Research focused on disease landscape and burden of disease for patients with heart failure (acute/chronic) /chronic kidney disease, including patients with or without type 2 diabetes (T2D)
  • Assessment of empagliflozin’s impact on holistic well-being of patients with type 2 diabetes (T2D) and one of the following: CVD, HF or CKD
  • Assessment of Cardiologist and Primary Care (PCP, APP) involvement in treatment of patients with type 2 diabetes (T2D) and one of the following: CVD, HF or CKD
  • Examining role of empagliflozin in transition-of-care models to outpatient setting in patients with type 2 diabetes (T2D) and one of the following: CVD, HF or CKD
  • Examining role of empagliflozin in collaborative care models of Cardio-renal-metabolic disease

Oncology

Solid Tumors

For drug only support, a submitted synopsis will be evaluated on an ongoing basis for strategic interest. Where interested, Boehringer Ingelheim will request a full proposal submission. All proposals will be reviewed on an ongoing basis; generally monthly.

For requests involving financial support, Boehringer Ingelheim will evaluate a synopsis application on an ongoing basis for strategic interest. Where interested, Boehringer Ingelheim will request a full proposal submission.

Afatinib IIS & ECR Objectives

  • Safety and efficacy of alternate dosing regimens (e.g., lower starting dose, treatment holidays, etc.)
  • Tumors driven by dysregulation of ErbB family members other than EGFR (e.g., HER2, HER3, HER4)
    • non-T790M acquired resistance to 1st/2nd generation EGFR TKIs
    • acquired resistance to 3rd generation TKIs following either first or second line use

Respiratory

Asthma

  • Evaluation of gaps in pharmacological management strategy for treatment of mild, moderate and severe asthma.
  • Assess impact of asthma in adult, adolescent and pediatric patients on Healthcare Resource Utilization HCRU (outpatient visits, ER visits, asthma exacerbation hospitalizations and associated costs)
  • Evaluate asthma pharmacotherapy received before and after asthma related hospitalization
  • Evaluate the impact of ICS dose and HCRU

COPD

  • Assess STIOLTO effectiveness in COPD population with early (Mild/Moderate) disease including impact on HCRU (Outpatient visits, ER visits, AECOPD Hospitalizations, All cause and COPD related 30/90 Re-Admission, exacerbation treatment, adverse reactions, and associated COPD costs).
  • Describe proportion and characteristics (e.g. Exacerbation history) of patients with COPD treated with ICS- containing therapy including triple therapy (any combination LAMA/LABA/ICS).
  • Evaluate clinical phenotypes and their impact on inhaler selection and use in COPD and contribution to patient preferences, outcomes and adherence (i.e. Suboptimal PIFR, Disease Severity)
  • Evaluate institution COPD disease management programs that include the Respimat as inhaler platform and its impact on HCRU

ILD/IPF

  • Studies investigating newer tools for interstitial lung disease (ILD) screening, earlier diagnosis, or disease assessment
  • Studies investigating the natural course of the disease in patients with ILD (including risk factors and predictors of disease progression)
  • Studies investigating management of ILD including:
    • Diagnosing and managing co-morbidities
    • Diagnosing and managing acute exacerbations
    • Evaluating and managing extra-pulmonary manifestations of patients with connective tissue disease (CTD)-ILD
    • Non-pharmacologic management, including supportive and palliative care, home monitoring programs, nurse support, rehabilitation, physical training, oxygen use, and other innovative digital tools

Biosimilars/CNS/Immunology

(Currently, proposals are not being accepted in this area at this time)

Cardiovascular

(Currently, proposals are not being accepted in this area at this time)

Back to External Research Grant Overview